Nolan Seim

Nolan Seim

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
NSNolan Seim
Nolan Seim
RPRamez H. W. Philips
Ramez H. W. Philips
LMLaura A. Matrka
Laura A. Matrka
BLBrittany Locklear
Brittany Locklear
MIMark Inman
Mark Inman
GEGarth F. Essig
Garth F. Essig

14 January 2019 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
PDF file
RPRamez Philips
Ramez Philips
NSNolan Seim
Nolan Seim
LMLaura Matrka
Laura Matrka
BLBrittany Locklear
Brittany Locklear
AMAaron C. Moberly
Aaron C. Moberly
GEGarth Essig
Garth Essig
Objective: To test the null hypothesis that there is no difference in patient cost savings between the telemedicine and traditional face‐to‐face approach. The second objective was to assess the financial impact on the peripheral healthcare system, as compared with staffing a conventional clinic with “on‐site” otolaryngologist.Methods: Twenty‐one patients were enrolled. To assess “patient‐benefit” cost savings, a model was formulated that would utilize a certified nurse practitioner (CNP) to conduct a general otolaryngology clinic at the peripheral site, as compared with having to travel to the tertiary referral center. A “peripheral site‐benefit” cost analysis was performed to assess costs of initiating and operating a telemedicine clinic at the peripheral site, compared with having an on‐site otolaryngologist.Results: The total patient‐benefit cost savings would be $182.09 per patient per encounter and $333.22 per patient annually. The fixed cost to the peripheral site to initiate the telemedicine system was $9,895. Two hundred sixty telemedicine encounters would be needed to offset the initial cost, and 537 encounters would be needed to surpass revenue of the conventional clinic.Conclusion: A real‐time telemedicine otolaryngology clinic provides significant cost savings for both patients and the peripheral healthcare system. This pilot study supports telemedicine as a cost‐effective approach to providing general otolaryngology care to rural patients.Level of Evidence: 4

11 January 2023 in Oral Oncology
Verified
Journal Article
Closed access
MHMargaret A. Heller
Margaret A. Heller
SNSarah C. Nyirjesy
Sarah C. Nyirjesy
RBRobert Balsiger
Robert Balsiger
NTNicholas Talbot
Nicholas Talbot
KVKyle K. VanKoevering
Kyle K. VanKoevering
NSNolan Seim
Nolan Seim

28 August 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ANAkash N. Naik
Akash N. Naik
TFTaylor Freeman
Taylor Freeman
MLMichael M. Li
Michael M. Li
SMScarlett Marshall
Scarlett Marshall
ATAkina Tamaki
Akina Tamaki
NSNolan Seim
Nolan Seim
Background/Objectives: Microvascular free tissue transfer has become essential to head and neck reconstruction and recent advancements in microvascular surgery have led to excellent surgical outcomes. However, there continues to be controversy and a stigma associated with the use of perioperative intravenous vasopressor agents among both surgeons and anesthesiologists. Due to concern for vasoconstriction of peripheral vasculature flowing to the denervated tissue flap, there remains concerns about potential thrombosis, decreased tissue perfusion and ultimately flap failure. This topic becomes even more important as vasopressors play an essential role in new Extended Recovery After Surgery (ERAS) protocols being put in place to optimize postoperative recovery for patients. The purpose of this study was to comprehensively review the role and safety as well as discuss current trends with intraoperative vasopressor agents in free tissue transfer for head and neck reconstruction. Methods: A scoping literature review was conducted of all studies that examined the use of vasopressor agents during head and neck free flap tissue transfer. Primary and secondary outcomes included free flap survival, arterial thrombosis, venous congestion, need for revision surgery, and other postoperative complications. Results: One prospective and nine retrospective studies were identified. Phenylephrine and ephedrine were the most common vasopressors reported; the rate of vasopressor use ranged from 53% to 85% and administration methods included both bolus and infusion. The included studies did not show any significant association between the use of vasopressors and free flap failure, pedicle thrombosis, or other flap complications. Conclusion: The administration of vasopressors during microvascular free tissue transfer for head and neck reconstruction does not seem to be associated with increased flap failure rates or other postoperative morbidities. Moreover, vasopressors may provide overall improved hemodynamic stability and help to limit overall fluid administration and subsequent postoperative complications. Additional prospective investigation is warranted to further elucidate and establish evidence-based recommendations regarding the type, timing, and dose of vasopressors to further enhance free flap survival and patient outcomes.

1 June 2016 in World Journal of Otorhinolaryngology - Head and Neck Surgery
Verified
Journal Article
Open access
NSNolan Seim
Nolan Seim
CWChadwick L. Wright
Chadwick L. Wright
AAAmit Agrawal
Amit Agrawal
Sentinel lymph node biopsy has become a well‐established and commonplace practice in many oncologic disease sites as a means to stage the regional lymphatics, avoid unnecessary surgery and decrease patient morbidity. In the head and neck, its role is well established for cutaneous melanoma with proven fidelity and survival benefit. Its role in use for other sites such as oral cavity carcinoma continues to develop with promising results from several recent trials. Although not widely adopted, the potential benefits of sentinel lymph node biopsy in the management of oral cavity carcinoma are apparent. Refinements in technology and protocols including development of novel radiopharmaceutical tracers, routine incorporation of detailed anatomic imaging, increasing surgeon experience and development of new intraoperative identification aids will likely lead to improvements in the use and accuracy of this technique.

25 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
EMEric V. Mastrolonardo
Eric V. Mastrolonardo
KNKathryn L. Nunes
Kathryn L. Nunes
PLPablo Llerena
Pablo Llerena
ANAnastasia Nikitina
Anastasia Nikitina
ASAnastasia Sobol
Anastasia Sobol
ALAdam J. Luginbuhl
Adam J. Luginbuhl
Purpose: We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders to immunotherapy and enhance their response. Patients and Methods: Patients with HNSCC were 3:1 randomized to receive nivolumab with or without BMS986205 orally daily (NCT03854032). In the combination arm, BMS986205 was initiated 7 days prior to nivolumab. Patients were stratified by human papillomavirus (HPV) status. Response-adaptive surgical timing involved response assessment by radiographic criteria 4 weeks after treatment with nivolumab in both arms. Nonresponders underwent surgical resection, whereas responders received 4 more weeks of randomized therapy before surgery. Biomarker analysis utilized pathologic treatment response (pTR) and RNA sequencing. Results: Forty-two patients were enrolled, and the addition of IDOi to nivolumab did not result in greater rate of radiographic response (P = 0.909). Treatment was well tolerated, with only 2 (5%) patients experiencing grade 3 immune-related adverse events. The addition of IDOi augmented rates of pTR in patients with high baseline IDO1 RNA expression (P < 0.05). Response-adaptive surgical timing demonstrated reliability in differentiating pathologic responders versus nonresponders (P = 0.009). A pretreatment NK cell signature, PD-L1 status, and IFN-γ expression in the HPV− cohort correlated with response. The HPV+ cohort found B-cell and cancer-associated fibroblast signatures predictive of response/nonresponse. Conclusions: Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting resistant nodes to immunotherapy. HPV status–dependent signatures predicting response to immunotherapy in HNSCC warrant further study.